Is cerebral microbleed prevalence relevant as a biomarker in amnestic mild cognitive impairment and mild Alzheimer's disease?

Publisher: Sage Publications Country of Publication: United States NLM ID: 101295103 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2385-1996 (Electronic) Linking ISSN: 19714009 NLM ISO Abbreviation: Neuroradiol J Subsets: MEDLINE

Publication: 2015- : Thousand Oaks, CA : Sage Publications
Original Publication: Bologna : Centauro

Alzheimer Disease/*diagnostic imaging ; Biomarkers/*cerebrospinal fluid ; Cerebral Hemorrhage/*diagnostic imaging ; Cognitive Dysfunction/*diagnostic imaging ; Magnetic Resonance Imaging/*methods; Aged ; Alzheimer Disease/cerebrospinal fluid ; Amyloid beta-Peptides/cerebrospinal fluid ; Amyloid beta-Peptides/genetics ; Apolipoproteins E/cerebrospinal fluid ; Case-Control Studies ; Cerebral Hemorrhage/cerebrospinal fluid ; Cognitive Dysfunction/cerebrospinal fluid ; Female ; Genotype ; Humans ; Male ; Neuropsychological Tests ; Polymerase Chain Reaction ; Prevalence ; tau Proteins/cerebrospinal fluid

Introduction The search for a reliable neuroimaging biomarker in Alzheimer's disease is a matter of intense research. The presence of cerebral microbleeds seems to be a potential biomarker. However, it is not clear if the presence of microbleeds has clinical usefulness to differentiate mild Alzheimer's disease and amnestic mild cognitive impairment from normal aging. We aimed to verify if microbleed prevalence differs among three groups: mild Alzheimer's disease, amnestic mild cognitive impairment due to Alzheimer's disease, and normal controls. Moreover, we studied whether microbleeds were associated with apolipoprotein E allele ɛ4 status, cerebrospinal fluid amyloid-beta, total and phosphorylated tau protein levels, vascular factors, and cognition. Methods Twenty-eight mild Alzheimer's disease patients, 34 with amnestic mild cognitive impairment and 36 cognitively normal elderly subjects underwent: magnetic resonance imaging with a susceptibility-weighted imaging sequence on a 3T scanner, apolipoprotein E genotyping and a full neuropsychological evaluation. Only amnestic mild cognitive impairment and mild Alzheimer's disease underwent cerebrospinal fluid analysis. We compared the groups and verified if microbleeds were predicted by all other variables. Results Mild Alzheimer's disease presented a higher prevalence of apolipoprotein E allele ɛ4 in relation to amnestic mild cognitive impairment and control group. No significant differences were found between groups when considering microbleed presence. Logistic regression tests failed to find any relationship between microbleeds and the variables. We performed three different regression models using different independent variables: Model 1 - amyloid-beta, phosphorylated tau protein, total tau, apolipoprotein E allele ɛ4 status, age, and sex; Model 2 - vascular risk factors, age, and sex; Model 3 - cognitive scores sex, age, and education. Conclusion Although microbleeds might be related to the Alzheimer's disease process, their presence is not a good candidate for a neuroimaging biomarker of the disease, especially in its early phases.

Braz J Psychiatry. 2007 Dec;29(4):324-9. (PMID: 17713697)
J Gerontol. 1982 May;37(3):323-9. (PMID: 7069156)
Neuropsychologia. 1979;17(1):49-54. (PMID: 431809)
Alzheimers Dement. 2011 May;7(3):270-9. (PMID: 21514249)
AJNR Am J Neuroradiol. 2015 Sep;36(9):1635-41. (PMID: 26228889)
Acta Neuropathol. 2005 Oct;110(4):345-59. (PMID: 16170565)
AJNR Am J Neuroradiol. 1999 Apr;20(4):637-42. (PMID: 10319975)
Lancet. 1996 Apr 27;347(9009):1141-5. (PMID: 8609748)
Arch Neurol. 2008 Jun;65(6):790-5. (PMID: 18541799)
Neurology. 2005 Oct 11;65(7):1045-50. (PMID: 16217057)
Stroke. 2007 Jun;38(6):1949-51. (PMID: 17510457)
Dement Geriatr Cogn Disord. 2006;22(1):8-14. (PMID: 16645275)
Neurology. 1993 Nov;43(11):2412-4. (PMID: 8232972)
Alzheimers Dement. 2011 May;7(3):263-9. (PMID: 21514250)
Arq Neuropsiquiatr. 2003 Sep;61(3B):777-81. (PMID: 14595482)
Brain. 2011 Feb;134(Pt 2):335-44. (PMID: 21257651)
J Psychiatr Res. 1975 Nov;12(3):189-98. (PMID: 1202204)
Alzheimers Dement. 2016 Apr;12(4):459-509. (PMID: 27570871)
Brain. 2010 Apr;133(Pt 4):1163-72. (PMID: 20375138)
J Alzheimers Dis. 2009;17(3):469-81. (PMID: 19363257)
Neurology. 2008 Apr 1;70(14):1208-14. (PMID: 18378884)
AJR Am J Roentgenol. 1987 Aug;149(2):351-6. (PMID: 3496763)
AJNR Am J Neuroradiol. 2016 Feb;37(2):215-22. (PMID: 26635284)
Stroke. 2006 Sep;37(9):2220-41. (PMID: 16917086)
AJNR Am J Neuroradiol. 2015 Apr;36(4):661-6. (PMID: 25523590)
Alzheimers Dement (Amst). 2015 Oct 03;1(4):455-63. (PMID: 27239524)
J Neurol. 2003 Dec;250(12):1496-7. (PMID: 14673587)
Lancet Neurol. 2009 Feb;8(2):165-74. (PMID: 19161908)
Neurology. 2013 Nov 26;81(22):1930-7. (PMID: 24174590)
J Alzheimers Dis Parkinsonism. 2016 Nov;6(6):. (PMID: 28042517)
NeuroRx. 2004 Apr;1(2):226-34. (PMID: 15717023)
Neurology. 1994 Dec;44(12):2308-14. (PMID: 7991117)
Ann N Y Acad Sci. 2002 Nov;977:169-72. (PMID: 12480748)
Neurol Clin. 2007 Aug;25(3):669-82, vi. (PMID: 17659184)
Lancet Neurol. 2008 Feb;7(2):184-90. (PMID: 18207116)
Arch Neurol. 2006 May;63(5):665-72. (PMID: 16682536)
Alzheimers Res Ther. 2014 Jun 11;6(3):33. (PMID: 24987468)
Stroke. 2009 Nov;40(11):3455-60. (PMID: 19762705)
Brain. 2007 Aug;130(Pt 8):1988-2003. (PMID: 17322562)

Keywords: Alzheimer’s disease; Microbleeds; biomarkers; mild cognitive impairment

0 (Amyloid beta-Peptides)
0 (Apolipoproteins E)
0 (Biomarkers)
0 (tau Proteins)

Date Created: 20170718 Date Completed: 20171219 Latest Revision: 20240327

20240327

PMC5602341

10.1177/1971400917720465

28714354